ACROBiosystems – Bispecific antibody targets and more


Bispecific antibodies (bsAbs) harness the specificities of two antibodies and combine them to simultaneously recognize different antigens or epitopes. This ‘two-target’ functionality has meant that interest in their use for therapeutic applications has increased considerably. With the development and maturity of bsAb technology platform, the combination selection of targets is becoming the key point of competition. Among the bsAb programs under development currently, the combination of CD3 and tumor surface targets are the most popular targets pairs. And the new targets of Immune cell will also provide more choice in targets combination in the future.

Related Page: Introduction of ACROBiosystems

Hot targets

Free samples for bsAb hot targets are available!

> MALS verified heterodimer
> High bioactivity and batch-to-batch consistency
> Bioactivity verified by clinical bispecific antibody
> Various tags and species
Learn more about CD3 proteins
> High purity and homogeneity
> High bioactivity verified
> Various tags and species
Learn more about immune checkpoint targets
> High purity and homogeneity
> High bioactivity verified
> Suitable for immunization and inhibitor
Learn more about CD47 proteins
Full length CD20 Proteins
> Authentic conformation
> Super bioactivity verified
> Exclusive Nanodisc technology
Learn more about CD20 proteins


More BsAb targets↓

CD3 CD19 CD20 CD38
CD40 CD47 IL-3 R alpha Her2
ErbB3 LAG-3 4-1BB PD-1
ROR1 VEGF R2 FAP IL-1 beta
IL-4 IL-6 R alpha IL-13 IL-17A
CD16 TNF-alpha ANGTP2 OX40
ICOS HGF B7-H3 TGF-beta 1
LRP-5 LRP-6 CEACAM-5 Mucin-1

Bioactivity analysis of bispecific antibody

The characterization and pharmacokinetic (PK)/PD assessment are vital. Quality attributes such as antigen specificity; affinity and on- and off-rates; avidity (for bispecific antibodies that target two molecules on the same cell); potency; process-related impurities such as aggregates, fragments, and homodimers; stability; and half-life may affect pharmacology and should be studied. On the other hand, as bispecific antibodies may present as a mixture of biologically active and inactive forms, it is important to identify the bispecific antibody form(s) that is most pharmacologically relevant to PK/PD assessment and to develop validated assays that measure the appropriate form(s) accordingly. Due to the synergetic effect BsAb brings, the dosage is relatively low. Therefore, it requires a more sensitive assay for analysis.


Case-study1: antigen-antibody affinity

Fig 1. Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3 X BCMA) and then add Biotinylated BCMA Fc,Avitag (Cat. No. BC7-H82F0) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL.


Case-study2: FcR-antibody affinity

Fig 2. Binding assay between bsAb and Fc receptor


Case-study3: Intact assay of bsAb

Fig 3. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay)


Methodology validation

Learn more about Bioactivity analysis of bispecific antibody


With a strong team of scientists, ACROBiosystems also provides high-quality integrated SPR&BLI analytical services. ACRO has served and collaborated with more than 100 customers from academia and industry. Our work supported multiple antibody drugs IND applications.

Click to learn more about SPR /BLI analytical service


See introduction of all products of ACROBiosystems.

Back to Top

Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.
TEL:029-851-9222 FAX:029-851-9220